See "Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation" on page 114-123.

Supplementary Table 1. Rates (per 100 PY) and Risks of Any First Adverse Events during the First Year of Treatment in Patients in ADA and VDZ

Variable	No. of events ADA/VDZ	Rates per 100 PY with CIs in ADA	Rates per 100 PY with CIs in VDZ
All	34/57	45.7 (32.7–64.0)	54.2 (41.8–70.3)
Disease			
Ulcerative colitis	11/25	58.7(32.5–105.9)	57.9 (39.1–85.7)
Crohn's disease	23/32	41.4 (27.5–62.3)	51.6 (36.5–72.9)
Age (yr)			
≤ 35	10/10	52.8 (28.4–92.2)	43.7 (23.5–81.3)
36–54	18/27	43.0 (27.1–68.3)	54.8 (37.6–79.9)
≥ 55	6/20	44.1 (19.8–98.2)	60.5 (39.0–93.7)
Sex			
Male	19/30	41.5 (26.4–65.0)	42.1 (29.4–60.2)
Female	15/27	52.6 (31.7–87.3)	79.5 (54.1–115.9)
Previous biological therapy			
None	15/4	43.7 (26.3–72.4)	23.3 (8.7–62.0)
1 Biological therapy	18/10	48.5 (30.6–67.0)	32.3 (17.4–60.1)
≥ 2 Biological therapies	1/43	34.5 (4.8–245.2)	75.3 (55.9–101.6)
Time from the last biological therapy			
No biologic therapies (naïve) or from more than 6 mo	18/25	42.0 (26.5–66.8)	50.9 (34.4–75.3)
≤ 6 mo	16/32	50.7 (31.0–82.7)	57.1 (40.4–80.1)
Indication to therapy			
Active disease	30/52	44.6 (31.2–63.8)	54.5 (41.5–71.5)
Post-surgery	-	-	-
Intolerant to previous biologic therapy	4/5	64.9 (24.4–173.0)	105.8 (44.0–254.3)
Azathioprine during the year before the start of the treatment			
No	29/51	42.3 (29.4–60.9)	56.3 (42.8–74.1)
Yes	5/6	85.8 (35.7–206.1)	41.1 (18.4–91.4)
Steroids during the year before the start of the treatment			
No	26/43	46.2 (31.4–67.9)	49.3 (36.6–66.5)
Yes	8/14	44.3 (22.1–88.5)	77.6 (45.9–130.9)
Azathioprine ongoing			
No	28/46	46.5 (32.1–67.3)	52.1 (39.0–69.6)
Yes	6/11	42.5 (19.1–94.5)	65.1 (36.0–117.6)
Steroids ongoing			
No	27/33	46.2 (31.7–67.4)	50.4 (35.8–60.9)
Yes	7/24	43.9 (20.9–92.1)	60.5 (40.5–90.2)

PY, person-years; ADA, adalimumab; VDZ, vedolizumab; CIs, confidence intervals.